Research Topics
Species | E PaiettaSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Expression of cell-surface antigens in acute promyelocytic leukaemiaElisabeth Paietta
New York Medical College, Valhalla, NY, USA
Best Pract Res Clin Haematol 16:369-85. 2003..Despite some significant antigenic differences (e.g. in CD34 expression), this surrogate marker profile for t(15;17) APL applies to both the M3 and the M3v FAB phenotypes and to all three isoforms of the PML/RARalpha transcript...
Minimal residual disease in acute myeloid leukemia: coming of ageElisabeth Paietta
Albert Einstein College of Medicine, Bronx, NY, USA
Hematology Am Soc Hematol Educ Program 2012:35-42. 2012....- Surrogate marker profiles for genetic lesions in acute leukemiasElisabeth Paietta
Montefiore Medical Center North Division, Immunology Laboratory, Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA
Best Pract Res Clin Haematol 23:359-68. 2010..As the list of therapeutic targets grows, the role of surrogate antigen profiles will grow, as they can predict for the efficacy of targeted approaches in lieu of expensive, time-consuming and not always accessible genetic analyses... - A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypesE Paietta
Immunology Laboratory, Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
Cytometry B Clin Cytom 59:1-9. 2004.... - Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemiasElisabeth Paietta
Our Lady of Mercy Cancer Center Immunology Laboratory, 600 East 233rd St, Bronx, NY 10466, USA
Blood 104:558-60. 2004..Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL... - Comments on the 2001 WHO proposal for the classification of haematopoietic neoplasmsElisabeth Paietta
New York Medical College, Valhalla, NY, USA
Best Pract Res Clin Haematol 16:547-59. 2003..By introducing some state-of-the-art classification modalities, some of which are still awaiting confirmation, this chapter also aims to spark excitement and provide a glimpse at the future... - How to optimize multiparameter flow cytometry for leukaemia/lymphoma diagnosisElisabeth Paietta
Our Lady of Mercy Cancer Center, 600 East 233rd Street, 10466, Bronx, NY, USA
Best Pract Res Clin Haematol 16:671-83. 2003.... - Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneityE Paietta
Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
Am J Hematol 66:189-96. 2001..Epstein-Barr virus (EBV) sequences were detected in one T- and both B-lymphoid cases. Our data suggest that CD56 is expressed at a precursor stage common to the T- and the B-cell lineage... - Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trialsE Paietta
Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
Leukemia 17:1544-50. 2003..Although not statistically significant, the observed association between low CD65s expression and decreased CR rate only in patients over the age of 55 is intriguing... - Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)P H Wiernik
Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
Leukemia 18:1605-10. 2004..025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression... - Anticipation in familial chronic lymphocytic leukaemiaP H Wiernik
Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA
Br J Haematol 113:407-14. 2001..A significant difference was observed between the ages of onset of the child generation and the SEER population (P < 0.00001), but not between the parent generation and the SEER population. Anticipation characterizes familial CLL... - Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?E Paietta
Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
Bone Marrow Transplant 29:459-65. 2002..This discussion intends to redefine MRD into some biologically relevant subcategories which may warrant their own independent terminology... - Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxideY Sun
Department of Oncology, Montefiore Medical Center, Bronx, NY, USA
Leukemia 18:1258-69. 2004..25 microM ATO stimulated limited atypical maturation. These findings suggest that AP-1060 will be useful for further assessing molecular elements involved in APL progression and drug response/resistance... - Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology GroupMartin S Tallman
Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
J Clin Oncol 22:1276-86. 2004..This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML, and to identify differences in M5a and M5b... - Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemiaAdolfo A Ferrando
Department of Pediatric Oncology, Dana-Farber Cancer Institute/Harvard School of Public Health, 44 Binney Street, Mayer-630, Boston 02115, MA, USA
Lancet 363:535-6. 2004..Furthermore, our findings lead to questions about whether stem-cell transplantation in first remission is necessary for effective treatment of patients in the low-risk subgroup of patients with TLX1 oncogene expression... - Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997Michael R Grever
Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
J Clin Oncol 25:799-804. 2007..1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome... - Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemiasDejan Juric
Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
J Clin Oncol 25:1341-9. 2007..To identify gene expression patterns and interaction networks related to BCR-ABL status and clinical outcome in adults with acute lymphoblastic leukemia (ALL)... - A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupJacob M Rowe
Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Haifa 31096 Israel
Blood 103:479-85. 2004..Priming with hematopoietic growth factor did not improve response when compared with placebo. Furthermore, delaying induction therapy in older adults may lead to a lower complete remission rate...